[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:bladder-carcinoma:erbb2-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Bladder Carcinoma","ERBB2 Gene",5,[8,16,23,30,36],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT03740256","Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors",[12],"Phase 1","RECRUITING","2026-08-26T02:16:17.877565Z","2026-05-05T02:43:28.644039Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05417594","Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies",[20],"Phase 1\u002FPhase 2","2026-08-26T02:18:54.586325Z","2026-05-05T02:43:28.529406Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06760819","A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)",[27],"Phase 2","2026-08-26T02:17:10.213717Z","2026-05-05T02:43:26.692781Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT06253871","A Phase 1\u002F1b Study of IAM1363 in HER2 Cancers",[12],"2026-08-26T02:18:31.944757Z","2026-05-05T02:35:31.700916Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT07124000","DESTINY-PANTUMOUR04",[],"2026-08-26T02:15:24.145250Z","2026-05-13T02:55:06.658082Z"]